Pacira price target raised to $26 from $22 at RBC Capital

RBC Capital raised the firm’s price target on Pacira (PCRX) to $26 from $22 and keeps a Sector Perform rating on the shares. The company’s settlement of litigation for generic Exparel, which provides some closure to over a year’s worth of overhang and uncertainty for shares, is a win for the company and the Exparel franchise, bringing needed clarity as well as five years of protection to potentially realize the benefits of internal drivers such as GPO contracting and NOPAIN across the surgical segments, the analyst tells investors in a research note.